Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
When used in concert, RASSF1A hypermethylation in sputum and exhaled breath analysis are complementary for lung cancer diagnosis, with 100% sensitivity in this series.
|
24915850 |
2014 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We observed a strong association between MTHFR hypermethylation in lung cancer and tobacco smoking, whereas methylation levels of CDH1, CDKN2A, GSTP1, and RASSF1A were not associated with smoking, indicating that tobacco smoke targets specific genes for hypermethylation.
|
19118009 |
2009 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We find that lung cancer cells with RASSF1A promoter methylation display constitutive nuclear YAP1 accumulation and expression of prolyl 4-hydroxylase alpha-2 (P4HA2) which increases collagen deposition.
|
31268606 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined 514 cases of NSCLC and 84 corresponding nonmalignant lung tissues from 4 countries (USA, Australia, Japan and Taiwan) for the methylation status of 7 genes known to be frequently methylated in lung cancers [p16, RASSF1A (RAS association domain family 1), APC, RARbeta, CDH13, MGMT and GSTP1].
|
12455028 |
2003 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined the frequency of aberrant promoter methylation of the p16, adenomatous polyposis coli (APC), H-cadherin (CDH13), glutathione S-transferase P1 (GSTP1), O6-methylguanine-DNA-methyltransferase (MGMT), retinoic acid receptor beta-2 (RAR beta), E-cadherin (CDH1), and RAS association domain family 1A (RASSF1A) genes in 198 tumors consisting of small cell lung cancers [SCLCs (n = 43)], non-small cell lung cancers [NSCLCs (n = 115)], and bronchial carcinoids (n = 40).
|
12467239 |
2001 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line.All statistical tests were two-sided.
|
11333291 |
2001 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also studied possible genes downstream of RASSF1A in 16 primary non-small cell lung cancers and found that the expressions of SM22 and SPARC were significantly downregulated in RASSF1A-hypermethylated tumors.
|
15922865 |
2005 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using quantitative methylation-specific PCR, we found that the index of methylation (IM), calculated as IM = 100 × [copy number of methylated/(copy number of methylated + unmethylated gene)], for the RASSF1A and RARB2 genes in the cirDNA isolated from blood plasma and cell-surface-bound cirDNA was elevated 2- to 3-fold in lung cancer patients compared with healthy donors.
|
23806794 |
2013 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transfection of RASSF1A suppressed the growth of lung cancer cells in vitro and in nude mice.
|
11429703 |
2001 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our findings suggest that RASSF1C, unlike RASSF1A, is not a tumor suppressor but rather stimulates lung cancer cell proliferation.
|
16891396 |
2006 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To identify the significance of a support vector machine (SVM) model and a decision tree (DT) model for the diagnosis of lung cancer combined with the detection of fragile histidine triad (FHIT), RAS association domain family 1 (RASSF1A) and cyclin-dependent kinase inhibitor 2A (p16) promoter methylation levels and relative telomere length (RTL) of white blood cells from peripheral blood DNA.
|
27716889 |
2017 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To gain insight into RASSF1A functions in an unbiased manner, we have characterized the expression profile of a lung cancer cell line (A549) transfected with RASSF1A.
|
14500366 |
2003 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three bona fide lung cancer tumor suppressor genes namely RBSP3 (AP20 region),NPRL2 and RASSF1A (LUCA region) were identified in the 3p21.3 region.
|
20193080 |
2010 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study examined effects of cigarette smoke condensate (CSC) on expression and promoter methylation profile of critical genes (DAPK, ECAD, MGMT, and RASSF1A) involved in lung cancer development in different human lung cell lines.
|
23174910 |
2013 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests, for the first time, that RASSF1A Ala133Ser polymorphism may contribute to cancer susceptibility, especially for lung cancer.
|
24870779 |
2014 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the high methylation statuses of p16, RASSF1A, or FHIT genes were associated with a significantly increased risk of lung cancer; the risk of lung cancer increased as the methylation status increased.
|
23614702 |
2013 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the RASSF1 Ala133Ser SNP is associated with development of lung cancer, especially of lung adenocarcinoma.
|
16125301 |
2006 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that RASSF1A promoter polymorphisms affect RASSF1A expression, further contributing to the genetic susceptibility to lung cancer.
|
18313166 |
2008 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that starting smoking under age 18 is an independent risk for RASSF1A hypermethylation, thus identifying a molecular alteration related to the epidemiologic effect of teenage smoking as a lung cancer risk.
|
15540210 |
2005 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest that serum RASSF1A hypermethylation is a promising molecular biomarker for lung cancer diagnosis.
|
17267069 |
2007 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The risk model showed that 36% of lung cancer patients were defined as "high risk" (≥ 60% chance on lung cancer) based on RASSF1A hypermethylation in Set 1.The model was reproducible in Set 2.
|
24598366 |
2014 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The QMSP analysis of RASSF1A hypermethylation enabled a highly specific distinction between patients diagnosed with lung cancer and those with nonneoplastic lung disease.
|
16444703 |
2006 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of the study was to explore the application of artificial neural network model in the auxiliary diagnosis of lung cancer and compare the effects of back-propagation (BP) neural network with Fisher discrimination model for lung cancer screening by the combined detections of four biomarkers of p16, RASSF1A and FHIT gene promoter methylation levels and the relative telomere length.
|
27766520 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The panel of <i>RASSF1A, 3OST2</i> and <i>PRDM14</i> detected 28% (95% CI 11% to 44%) of lung cancer cases within 2 years, with specificity of 90% (95% CI 86% to 94%).
|
27496969 |
2017 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The overall results suggested that smokers with lung cancer had a 1.297-fold (95% CI: 1.066~1.580, p=0.010, p=0.087) higher risk for RASSF1A gene hypermethylation than the non-smokers.
|
25339045 |
2014 |